Related Experiment Video

Updated: Feb 16, 2026

Characterization of Metabolic Status in Nonhuman Primates with the Intravenous Glucose Tolerance Test
06:59

Characterization of Metabolic Status in Nonhuman Primates with the Intravenous Glucose Tolerance Test

Published on: November 13, 2016

11.4K

One-hour post-load plasma glucose level is associated with a worse metabolic profile in children with GH deficiency

A Ciresi1, C Giordano2

  • 1Section of Endocrinology, Biomedical Department of Internal and Specialist Medicine (DIBIMIS), University of Palermo, Piazza delle Cliniche 2, 90127, Palermo, Italy.

Journal of Endocrinological Investigation
|December 18, 2017
PubMed

Insights

Children with higher 1-hour plasma glucose (1hPG) during an oral glucose tolerance test (OGTT) show altered glucose metabolism and lipid profiles. This 1hPG level may help identify children needing closer monitoring during growth hormone treatment (GHT).

Area of Science:

  • Pediatric Endocrinology
  • Metabolic Disorders
  • Growth Hormone Therapy

Background:

  • Elevated 1-hour plasma glucose (1hPG) after oral glucose tolerance test (OGTT) in children predicts future glucose metabolism issues.
  • Growth hormone deficiency (GHD) can impact metabolic health.

Purpose of the Study:

  • To metabolically characterize children with GHD based on their 1hPG levels.
  • To assess the impact of growth hormone treatment (GHT) on metabolic parameters in GHD children with varying 1hPG levels.

Main Methods:

  • Fifty-one GHD children were grouped by baseline 1hPG and compared to 50 controls.
  • Evaluated auxological parameters, IGF-1, glucose/insulin during OGTT, lipid profiles, oral disposition index (DIo), Homa-IR, and insulin sensitivity index (ISI) at baseline and after 12 months of GHT.

Main Results:

  • GHD children had higher baseline 1hPG, LDL, and lower HDL compared to controls.
  • Children with higher 1hPG showed decreased DIo and poorer insulin sensitivity (ISI Matsuda) after GHT.
  • Baseline 1hPG correlated positively with Homa-IR and LDL, and negatively with ISI Matsuda and DIo.

Conclusions:

  • Baseline 1hPG is a valuable tool for identifying GHD children at higher metabolic risk.
  • Children with elevated 1hPG may require enhanced metabolic surveillance during GHT.
Abstract

Keywords:
GH treatmentGrowth hormoneInsulin secretionInsulin sensitivityMetabolism

More Related Videos

Study of In Vivo Glucose Metabolism in High-fat Diet-fed Mice Using Oral Glucose Tolerance Test OGTT and Insulin Tolerance Test ITT08:13

Study of In Vivo Glucose Metabolism in High-fat Diet-fed Mice Using Oral Glucose Tolerance Test OGTT and Insulin Tolerance Test ITT

Published on: January 7, 2018

71.9K
A RAPID Method for Blood Processing to Increase the Yield of Plasma Peptide Levels in Human Blood11:36

A RAPID Method for Blood Processing to Increase the Yield of Plasma Peptide Levels in Human Blood

Published on: April 28, 2016

9.9K

Related Concept Videos

Hypoglycemia and Glucagon01:15

Hypoglycemia and Glucagon

Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...
1.0K
Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses...
256
Insulin: Dosing Regimen and Adverse Effects01:16

Insulin: Dosing Regimen and Adverse Effects

Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
857
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test01:22

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess...
212
Diabetes: Symptoms, Diagnosis, and Complications01:15

Diabetes: Symptoms, Diagnosis, and Complications

For most patients, experiencing several weeks of polyuria, polydipsia, fatigue, and significant weight loss may indicate the presence of diabetes. Furthermore, adults displaying the phenotypic appearance of type 2 diabetes (particularly those who are obese and not initially insulin-requiring), may have islet cell autoantibodies, suggesting autoimmune-mediated β cell destruction and a diagnosis of latent autoimmune diabetes of adults (LADA). The categorization of glucose homeostasis is...
2.4K
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption01:23

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption

Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
323